Knoflach F, Benke D, Wang Y, Scheurer L, Lüddens H, Hamilton B J, Carter D B, Mohler H, Benson J A
Institute of Pharmacology, University of Zürich, Switzerland.
Mol Pharmacol. 1996 Nov;50(5):1253-61.
We characterized modulation of the gamma-aminobutyric acid (GABA)-evoked responses of the diazepam-insensitive alpha 4 beta 2 gamma2 and alpha 6 beta 2 gamma 2 recombinant GABAA receptors. The partial agonist bretazenil potentiated the responses of both receptors with similar dose dependence but with a higher maximal enhancement at the alpha 4 beta 2 gamma 2 receptor. The bretazenil-induced potentiation was reduced by the benzodiazepine antagonist flumazenil. At a high concentration (10 microM), flumazenil was a weak potentiator of the GABA response. The partial agonist imidazenil was inactive. The imidazobenzodiazepine inverse agonist Ro 15-4513, which is known to bind with high affinity to the alpha 6 beta 2 gamma 2 receptor, potentiated the GABA responses of the alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2 receptor subtypes with similar dose dependence over the concentration range of 0.1-10 microM. Methyl-6, 7-dimethoxy-4-ethyl-beta-carboline, a beta-carboline inverse agonist, had a similar potentiating effect when tested at a concentration of 10 microM. The alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2 receptor-mediated currents had equal sensitivities to furosemide and Zn2+ ions, both of which reduced the GABA-evoked responses. The alpha 6 beta 2 gamma 2 receptor but not the alpha 4 beta 2 gamma 2 receptor exhibited a low level of spontaneous activity in the absence of GABA; this resting current could be directly potentiated by Ro 15-4513, methyl-6,7-dimethoxy-4-ethyl-beta-carboline, bretazenil and flumazenil and was blocked by picrotoxin. Thus, although the alpha 4 beta 2 gamma 2 receptors are insensitive to benzodiazepine binding site full agonists, such as diazepam, they can be modulated by certain ligands acting as partial and inverse agonists at diazepam-sensitive receptors and thereby contribute to the respective pharmacological profiles.
我们对不敏感于地西泮的α4β2γ2和α6β2γ2重组GABAA受体的γ-氨基丁酸(GABA)诱发反应的调节进行了表征。部分激动剂布雷替奈唑以相似的剂量依赖性增强了两种受体的反应,但在α4β2γ2受体处具有更高的最大增强作用。布雷替奈唑诱导的增强作用被苯二氮䓬拮抗剂氟马西尼减弱。在高浓度(10μM)时,氟马西尼是GABA反应的弱增强剂。部分激动剂咪达唑仑无活性。已知与α6β2γ2受体高亲和力结合的咪唑并苯二氮䓬反向激动剂Ro 15-4513在0.1-10μM的浓度范围内以相似的剂量依赖性增强了α4β2γ2和α6β2γ2受体亚型的GABA反应。β-咔啉反向激动剂甲基-6,7-二甲氧基-4-乙基-β-咔啉在10μM浓度下测试时具有类似的增强作用。α4β2γ2和α6β2γ2受体介导的电流对速尿和Zn2+离子具有相同的敏感性,这两种离子均降低了GABA诱发的反应。在没有GABA的情况下,α6β2γ2受体而非α4β2γ2受体表现出低水平的自发活性;这种静息电流可被Ro 15-4513、甲基-6,7-二甲氧基-4-乙基-β-咔啉、布雷替奈唑和氟马西尼直接增强,并被印防己毒素阻断。因此,尽管α4β2γ2受体对苯二氮䓬结合位点的完全激动剂(如地西泮)不敏感,但它们可被在对苯二氮䓬敏感的受体处作为部分激动剂和反向激动剂起作用的某些配体调节,从而有助于各自的药理学特征。